Ajanta Pharma Limited stock analysis
Want to see IN:AJANTPHARM full AI Analyst Report?
Ajanta Pharma Limited (AJANTPHARM) Stock Price & Analysis
AJANTPHARM Stock Chart & Stats
- Day’s Range
- INR 3,304.00 - INR 3,379.95
- 52-Week Range
- INR 2,446.35 - INR 3,796.95
- Previous Close
- INR 3,358.70
- Volume
- N/A
- Average Volume (3M)
- 20.01K
- Market Cap
- INR 413.76B
- Enterprise Value
- INR 447.23B
- Total Cash (Recent Filing)
- INR 6.80B
- Total Debt (Recent Filing)
- INR 1.54B
- Price to Earnings (P/E)
- 32.8
- Beta
- 0.19
- Next Earnings
- Feb 03, 2027 (Est.)
- EPS Estimate
- 23.7
- Last Dividend Ex-Date
- Aug 05, 2026
- Dividend Yield
- 0.97%
Bulls Say, Bears Say
Bulls Say
Steady Growth And Profitability
Sustained revenue growth alongside historically strong net and operating margins indicates that Ajanta Pharma has maintained healthy commercial execution. This combination supports reinvestment, resilience across therapeutic areas, and the potential for earnings to compound over the next several quarters.
Conservative Balance Sheet
Low leverage gives Ajanta Pharma meaningful financial flexibility to fund operations, pursue growth, and absorb business volatility without excessive financing pressure. Consistently strong return on equity also indicates that the company has historically converted its capital base into profitable growth.
Diversified Specialty Portfolio
A broad prescription-led portfolio across several therapeutic areas and geographies reduces reliance on any single product category. Branded and generic formulations also provide multiple routes to market, supporting a more durable commercial base than a narrowly concentrated product portfolio.
Bears Say
FY2026 Margin Compression
The FY2026 margin decline indicates that recent revenue growth has not translated into equally stable profitability. If mix, pricing, or cost pressures persist, they could reduce operating leverage and limit the earnings benefit of continued sales expansion over the medium term.
Weaker Cash Conversion
Weaker conversion of accounting profit into operating cash reduces the predictability and flexibility of Ajanta Pharma’s financial performance. Working-capital swings or higher cash investment can constrain internally funded growth and make reported earnings less representative of available cash.
Debt Increased In FY2026
The FY2026 increase in debt is a developing balance-sheet watch point even though overall leverage remains low. Continued borrowing could gradually raise financing obligations and reduce the conservative financial flexibility that has supported the company’s historical resilience.
Ajanta Pharma Limited News
AJANTPHARM FAQ
What was Ajanta Pharma Limited’s price range in the past 12 months?
What is Ajanta Pharma Limited’s market cap?
When is Ajanta Pharma Limited’s upcoming earnings report date?
How were Ajanta Pharma Limited’s earnings last quarter?
Is Ajanta Pharma Limited overvalued?
Does Ajanta Pharma Limited pay dividends?
What is Ajanta Pharma Limited’s EPS estimate?
How many shares outstanding does Ajanta Pharma Limited have?
What happened to Ajanta Pharma Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ajanta Pharma Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Ajanta Pharma Limited
Established in 1973 and headquartered in Mumbai, India, Ajanta Pharma Limited operates as a specialized pharmaceutical enterprise. This company, along with its subsidiaries, is dedicated to the development, manufacturing, and commercialization of finished dosage forms. Its extensive product range caters to numerous therapeutic categories, such as anti-infectives (antibiotic, anti-malarial), chronic disease management (anti-diabetic, cardiology), women's health (gynecology), pediatrics, respiratory ailments, general health, dermatology, ophthalmology, and pain management. Notable products include multivitamins, antibiotics, eye drops, and cough syrups. Ajanta Pharma boasts a substantial international footprint, operating across India, Africa, other parts of Asia, the United States, and additional global markets. Furthermore, it supplies its pharmaceutical offerings to various government entities, including armed forces, public hospitals, and governmental procurement departments.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Yogesh Mannalal Agrawal
- Employees
- 10,421
- Website
- www.ajantapharma.com
- Address
- Ajanta House, Mumbai, MA, 400 093, IN
Ajanta Pharma Limited (AJANTPHARM) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 4 | 12 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 2 | 0 | 10 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| IN:EMCUREEmcure Pharmaceuticals Limited | ||
| IN:GLENMARKGlenmark Pharmaceuticals Limited | ||
| IN:IPCALABIPCA Laboratories Limited | ||
| IN:WOCKPHARMAWockhardt Limited |









